Trial Profile
Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary) ; Latanoprost/netarsudil
- Indications Open-angle glaucoma
- Focus Pharmacodynamics
- 12 Apr 2020 Planned End Date changed from 1 Apr 2020 to 1 Jan 2021.
- 12 Apr 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Jan 2021.
- 28 Jan 2020 New trial record